Wockhardt Limited — Updates, 28-07-2025: Press Release

Wockhardt's novel antibiotic, Zaynich® (Zidebactam/Cefepime), successfully treated a severe pan-drug resistant infection in a US liver transplant patient, as detailed in a leading UK medical journal. This critical case involved pathogens resistant to all available antibiotics. The patient showed remarkable clinical improvement and remained infection-free, enabling a successful transplant. This validates Zaynich®'s efficacy for extensively drug-resistant infections, significantly strengthening Wockhardt's antibiotic discovery pipeline and enhancing the drug's global market potential ahead of authorization.